Organization (Academic)
Rockefeller University
ClinicalTrials.gov lists Rockefeller University as lead sponsor of 122 trials. It has 16 active development programs and 25 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Rockefeller University: 122 lead-sponsored trials and 1 legal-entity registration.
Disease areas (88)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 26 |
| Obesity | 21 |
| Acquired Immunodeficiency Syndrome | 14 |
| Insulin Resistance | 8 |
| Psoriasis | 8 |
Showing 5 of 88 disease areas.
Trials by start year as sponsor or collaborator (32)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 9 |
| 2020 | 9 |
| 2019 | 3 |
| 2018 | 6 |
| 2017 | 6 |
Showing 10 of 32 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (16)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| 3BNC117 | HIV Infections | Phase 2 | 4 |
| 3BNC117 | Acquired Immunodeficiency Syndrome | Phase 2 | 4 |
| HepB mAb19 | Hepatitis B | Phase 1 | 1 |
| 3BNC117-LS | Acquired Immunodeficiency Syndrome | Phase 1 | 4 |
| 3BNC117-LS | HIV Infections | Phase 1 | 4 |
Showing 5 of 16 active programs.
Approved assets (25)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Hepatitis B Vaccine | 2 |
| Amoxicillin Oral Capsule | 1 |
| Harvoni | 1 |
| Statins | 1 |
| Recombivax | 1 |
Showing 5 of 25 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 39% hit target (n=33) | 47% on time (n=32) |
Journals published in (121)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Nature | 8 |
| The Journal of infectious diseases | 6 |
| The New England journal of medicine | 6 |
| PloS one | 5 |
| The Journal of allergy and clinical immunology | 5 |
Showing 5 of 121 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 735 | 73 | 2025-12-23 |
Financing and grant events (773)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-18 | NIH grant | 768,000 | Reporter |
| 2025-09-16 | NIH grant | 542,457 | Reporter |
| 2025-09-12 | NIH grant | 3,614,945 | Reporter |
| 2025-09-09 | NIH grant | 211,875 | Reporter |
| 2025-09-08 | NIH grant | 1,678,554 | Reporter |
Showing 5 of 773 events.
Organization relationships (30)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 10 |
| Weill Medical College of Cornell University | Co sponsors trial with | 8 |
| Aaron Diamond AIDS Research Center | Co sponsors trial with | 4 |
| Mount Sinai Health System | Co sponsors trial with | 3 |
| International AIDS Vaccine Initiative | Co sponsors trial with | 3 |
Showing 5 of 30 relationships.
Latest dated events (1,670)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 1,670 events.
Biomarker capability evidence (360)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACD | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACHE | Trial collaborator | Named in trial inclusion criteria |
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 360 evidence rows.
Biomarkers this organization publishes on (385)
Shown in this order: most publications first.
Showing 5 of 385 biomarkers.
On Scientist.com
Rockefeller University is linked to 2 research suppliers in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Rockefeller University - Flow Cytometry Resource Center on Scientist.com
For prices, more details, or to contact Rockefeller University - Flow Cytometry Resource Center, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.